FIGURE 3 | The relations between PILE and clinical ef fi cacy of immunotherapy. (A) Overall best response in low and high PILE groups. (B) DCB and NDB patients in low and high PILE groups. (C) DOR for patients in low PILE group and high PILE groups. CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; ORR, objective response rate; DCR, disease control rate; DOR, duration of response; DCB, durable clinical bene fi t; NDB, non-durable clinical bene fi t.